Liver: Functions, Diseases, and Management

Liver: Functions, Diseases, and Management

  • The liver is described as the largest organ that stores blood, transforms it into chemicals for metabolic needs, and secretes bile used for digestion and fat absorption.
  • It removes waste products from the bloodstream and secretes them into bile, which is stored in the gall bladder and emptied into the small intestine.
  • Circulation to the liver is hepatic by dual supply: 80% from the portal vein (nutrient-rich but relatively low in oxygen) and 20% from the hepatic artery (oxygen-rich). The mixing of this blood occurs in the liver, exposing hepatocytes to both nutrients and oxygen.
  • The liver has three major functions: storage, metabolism, and protection (detoxification).

Blood supply, storage, and bile components

  • Storage:
    • Vitamins stored in the liver include vitamins A, D, E, K and vitamin B12. Vitamins A, D, E, K are fat-soluble and require bile for absorption. If bile production is decreased, absorption of these vitamins decreases.
    • Vitamin K deficiency can lead to bleeding risk.
    • In liver failure, high PT/INR can occur due to decreased vitamin K–dependent clotting factor synthesis and/or poor bile-mediated vitamin absorption.
  • Protection and detoxification:
    • Kupffer cells clear old red blood cells and pass components back to hepatocytes.
    • The liver detoxifies toxins by breaking them down with cytochrome enzymes; this is a key protective role.
    • First-pass metabolism: the liver processes many drugs and alcohol, which can contribute to hepatotoxicity if overwhelmed.
  • Metabolic storage and processing:
    • The liver stores glycogen (carbohydrates) and triglycerides and lipoproteins (lipids).
    • Bilirubin: pigment from hemoglobin breakdown. The liver processes bilirubin from the blood and excretes it into bile. High bilirubin causes jaundice.
  • Significance of bile:
    • Bile is produced by hepatocytes, stored in the gall bladder, and released into the small intestine to aid fat digestion.

Metabolic processes in the liver

  • Glucose handling:
    • After a meal, glucose is taken into the portal vein and converted to glycogen for storage in hepatocytes.
    • When energy is needed, glycogen is converted back to glucose and released in small amounts.
    • When there is excess glucose, amino acids from protein breakdown are used to synthesize glucose (glucogenesis). Note: the transcript uses the term "glucogenesis"; the standard term is gluconeogenesis. Ammonia is a byproduct of amino acid metabolism in this process and is toxic to the brain if elevated.
  • Protein metabolism:
    • The liver synthesizes most proteins (including albumin and many clotting factors); the transcript notes synthesis of protein but contains a misstatement ("glycogen aglobulin"). In reality, plasma proteins are produced by the liver, while immunoglobulins are produced by plasma cells elsewhere.
    • It also metabolizes fat and contributes to production of ketone bodies when glucose is low for energy.
  • Drug and toxin metabolism:
    • The liver metabolizes Tylenol (acetaminophen), alcohol, sedatives, anesthetics, barbiturates, amphetamines, and other drugs.
    • This metabolism can contribute to hepatotoxicity with excessive exposure or alcohol use (first-pass effect).
    • Patients with liver failure should avoid hepatotoxic substances (e.g., excessive alcohol, drugs metabolized by the liver, St. John’s wort).

Clinical assessment and diagnostics for liver disease

  • Comprehensive assessment for a patient with liver disease includes:
    • History: onset and nature of symptoms, risk factors, travel history, occupational exposure, recreational drug use, acetaminophen consumption, and alcohol use (risk thresholds noted as 4 glasses of wine/beer or mixed drinks per day for men (60–80 g ethanol) and 4 per day for women (40–60 g ethanol)).
    • Symptoms to screen for: unexplained bleeding, jaundice, weakness, edema, melena, fatigue, pruritus, abdominal pain, increasing abdominal girth, fever, weight gain, changes in mental status.
    • Physical signs: jaundice (skin ideal but eyes/oral mucosa can reveal jaundice when skin color is dark), muscle wasting, edema, spider angiomas, tremor, cognitive changes, asterixis (involuntary hand flapping) during hepatic encephalopathy.
    • Diagnostics:
    • Liver function tests: AST, ALT, bilirubin, alkaline phosphatase, LDH, PT/INR, lipid panel.
    • Imaging: abdominal ultrasound (liver density and size, biliary tree), CT or MRI as needed.
    • For ascites: paracentesis to remove fluid; monitor fluid for infection and composition (albumin, protein, culture).
  • Understanding portal venous flow and portal hypertension (conceptual):
    • Normal flow: Portal vein supplies nutrient-rich, low-oxygen blood from GI tract/pancreas/spleen to the liver; hepatic artery supplies oxygen-rich blood. Blood exits via the inferior vena cava to the heart.
    • Portal hypertension arises from obstruction to portal blood flow (e.g., cirrhosis). Blood backs up in portal venous system, causing splenomegaly and collateral circulation, leading to varices and ascites.
  • Important clinical note about portal hypertension: it cannot be measured with a standard blood pressure cuff; assessment is based on symptoms and imaging findings.

Types of liver disease covered

  • Viral hepatitis

    • Hepatitis A (A):
    • Transmission: fecal-oral; often asymptomatic, can be mild flu-like illness; sometimes jaundice and dark urine later.
    • Incidence: ~20–25% of hepatitis cases in the U.S.
    • Diagnostics: HAV antigen detectable in stool 7–10 days before symptoms; persists 2–3 weeks after symptoms; serum antibodies detectable after symptoms resolve.
    • Course: usually self-limiting; rarely progresses to cirrhosis; immunization provides protection; household contacts may require immunoglobulin if not vaccinated.
    • Prevention: safe food/hands, handwashing, water sanitation; vaccination recommended for travelers, IV drug users, chronic liver disease patients, and healthcare workers.
    • Diet and management: frequent small meals with IV fluids/glucose as needed; bed rest during acute stage with gradual ambulation.
    • Prognosis: ~90% recover in 6 months; <1% mortality; ~10% may become chronic carriers (rare for HAV). Immunization schedule: childhood 12–23 months with 3-dose series; adults per guidelines (2–3 doses).
    • Hepatitis B (B):
    • Transmission: blood, saliva, semen, vaginal secretions; can be transmitted via needles, maternal transmission at birth, and other mucous membrane exposures.
    • Incubation and course: long incubation; high risk of chronic infection; >90% recover within 6 months; about 10% become chronic carriers which can progress to chronic hepatitis.
    • Clinical features: fever, myalgias, loss of appetite, abdominal pain; jaundice may or may not be present; enlarged liver/spleen; posterior cervical lymphadenopathy may be enlarged.
    • Diagnosis: detection of specific hepatitis B antigens and DNA.
    • Prevention: screen blood donors; use of sterile equipment; immunization with a 3-dose vaccine series (childhood) or 2-dose series for adults; passive immunization (immunoglobulin) after exposure; when exposed, separate syringes/sites if giving vaccine and immunoglobulin.
    • Treatment goals: reduce infectivity and liver inflammation; avoid hepatotoxic substances; if anorexia/nausea severe, consider enteral/parenteral feeding; abstain from alcohol for 6 months after recovery; nutrition: ~2500–3000 kcal/day with ~1.2–1.5 g protein/kg/day.
    • Medications: hepatoprotective strategies; herbs such as milk thistle (silymarin) may be used; immunosuppressants if autoimmune.
    • Nursing considerations: gradual resumption of activity after jaundice resolves; psychosocial support; bed rest during acute phase; ensure safety and prevent transmission.
    • Hepatitis C (C):
    • Most common blood-borne infection in the U.S.; many are asymptomatic; often progresses to chronic hepatitis and cirrhosis; risk factors include IV drug use, high-risk sexual behavior, frequent transfusions, healthcare exposure.
    • Incubation is variable (15–160 days).
    • Disease course frequently chronic; it is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation.
    • Prevention: avoid IV drug use or use needle-exchange programs; standard precautions; blood product screening.
    • Treatment: historically challenging due to side effects; recently improved regimens have higher cure rates; vaccine not available.

  • Noninfectious and toxic hepatitis

    • Noninfectious hepatitis refers to chemical/drug-induced liver injury that causes hepatocellular necrosis and inflammation.
    • Common hepatotoxins: acetaminophen (leading cause of drug-induced hepatitis), certain antibiotics, and methyldopa.
    • Toxic (toxic) hepatitis presents with similar symptoms; may be more severe depending on exposure and time to antidote.
    • Management: remove toxin; supportive care; antidotes if available; potential progression to fulminant liver failure requiring transplantation.
    • Drug-induced hepatitis: manifestations can appear on the first day of use or after months; acetaminophen is a common culprit; stopping the drug leads to symptom improvement; sometimes short courses of corticosteroids are used; transplantation may be needed in severe cases.

  • NAFLD and NASH

    • NAFLD (non-alcoholic fatty liver disease): fat accumulation in hepatocytes not related to alcohol use; linked to dyslipidemia, genetics, and metabolic syndrome.
    • NASH (non-alcoholic steatohepatitis): inflammatory and fibrotic progression of NAFLD; can lead to cirrhosis.
    • Treatment emphasis: weight loss through diet and regular exercise; small but meaningful weight reductions can reduce hepatic fat and possibly fibrosis (e.g., 3–5% weight loss reduces fat; 7–10% weight loss can reduce scar tissue).

  • Cirrhosis

    • Definition: chronic disease with replacement of normal liver tissue by diffuse fibrosis, disrupting structure and function; the liver can regenerate but scar tissue forms and impedes normal architecture.
    • Pathophysiology: inflammation of bile ducts and hepatocytes leads to obstruction, new bile channels, and scar formation; progressive scar tissue replaces functional tissue; nutrition deficits worsen damage.
    • Types of cirrhosis:
    • Alcoholic cirrhosis: scarring around portal areas.
    • Postnecrotic cirrhosis: broad bands of scar tissue following an acute viral hepatitis episode.
    • Biliary cirrhosis: around the bile ducts due to chronic biliary obstruction (less common).
    • Clinical findings: nodular, bumpy liver on palpation/imaging; portal hypertension signs; decreased albumin; elevated alkaline phosphatase, bilirubin, ALT, AST; prolonged PT/INR.
    • Diagnostics: labs, ultrasound, CT, MRI; liver biopsy for confirmation.
    • Management goals: treat symptoms; address complications; avoid substances that worsen liver function; nutritional support; manage portal hypertension and ascites.
    • Medications and supportive care:
    • H2 blockers and antacids to reduce GI irritation and bleeding risk.
    • Vitamins and nutrition; especially in chronic alcohol users (thiamine/B1, folic acid, multivitamin).
    • Potassium-sparing diuretics (e.g., spironolactone) for ascites to minimize electrolyte shifts; diuretic regimens tailored to response.
    • Address portal hypertension with propranolol when indicated.
    • Milk thistle (silymarin) for jaundice is mentioned as an herbal approach.
    • Immunosuppressants if autoimmune.
    • Nursing management for cirrhosis: promote rest; measure abdominal girth and weight; respiratory optimization; gradual activity resumption; high-protein diet unless ascites present (ascites may require sodium restriction and diuretics); monitor for electrolyte and nutritional deficiencies; skin care due to pruritus and edema; fall prevention; oral hygiene; screen for bleeding risk due to coagulopathy.

  • Portal hypertension and related complications

    • Portal hypertension leads to collateral vessels forming in stomach, rectum, esophagus (esophageal varices) and abdomen (caput medusae); splenomegaly may occur due to congestion.
    • Esophageal varices are the most significant source of GI bleeding in cirrhosis; risk of life-threatening hemorrhage.
    • Ascites results from hypoalbuminemia and portal hypertension (third spacing of fluid into the peritoneal cavity).
    • Jaundice, pruritus, spider angiomas, reddened palms may be present.
    • Diagnosis of varices: endoscopy is standard; if varices bleed, urgent interventions include endoscopic therapies and pharmacologic control.

  • Esophageal variceal bleeding management

    • Immediate control: Octreotide (Sandostatin) to reduce bleeding; vasopressin can be used in urgent cases but is contraindicated with coronary artery disease due to vasoconstriction risk.
    • Endoscopic interventions: variceal ligation (banding) or sclerotherapy; balloon tamponade as a temporary measure in active, life-threatening bleed.
    • Medical management: avoid NSAIDs; maintain IV access; NG tube suction only when necessary and with caution to avoid provoking variceal rupture.
    • Nursing management: monitor for signs of bleeding, maintain hemodynamic stability, ensure IV fluids and potential blood products; oral hygiene; monitor INR and provide vitamin K if indicated; prepare for transfusion as needed.

  • Ascites management

    • Large-volume ascites can reach 20 L or more; look for increased abdominal girth and dyspnea.
    • Monitoring: abdominal circumference daily with fixed landmarks; weight monitoring; assess for edema and electrolyte abnormalities.
    • Diet and fluids: sodium restriction (often very low, e.g., 500 mg/day) to limit fluid accumulation; avoid salt substitutes containing ammonia; diuretics (prefer potassium-sparing) as tolerated; bed rest with semi-Fowler or high-Fowler position to aid breathing.
    • Paracentesis: ultrasound-guided drainage for relief; typically 5–6 L can be removed at one time; fluid sent for albumin, protein, culture analyses; albumin infusion to maintain oncotic pressure after large-volume taps.
    • Respiratory management: position and pacing to improve breathing; manage ammonia and electrolyte balance; monitor respiratory status closely.

  • Hepatic encephalopathy

    • A neuropsychiatric emergency that occurs in advanced liver disease; ammonia is a key etiologic factor but pathophysiology also involves reduced detoxification and shunting of blood.
    • Clinical manifestations range from subtle cognitive changes to asterixis (hand flapping), memory impairment, sleep-wake cycle disturbances, progressing to coma and seizures if untreated.
    • Stages: early stage with neuropsychiatric signs, possibly minimal hepatic encephalopathy, progressing to confused or lethargic states.
    • Management:
    • Lower serum ammonia with lactulose (or seculac): traps ammonia in the gut and promotes excretion in stool; target 2–3 soft stools per day; monitor for bloating, cramps, and hypokalemia due to stool losses.
    • Lactulose can be given via NG tube or enema if patient cannot swallow.
    • Nutritional management: maintain stable protein intake (avoid aggressive protein restriction unless necessary); consider amino acid supplementation in protein-intolerant patients; provide small, frequent meals plus late-night snack to support energy needs; avoid excess salt substitutes.
    • Nursing priorities: safety and prevention of falls; monitor mental status and ammonia levels; ensure stools are regular; watch for fluid and electrolyte imbalances; educate patient and family about progression and management.

  • Summary of key numerical and factual references from the transcript

    • Portal vein contribution to liver blood supply: 80ext%80 ext{\%}; hepatic artery contribution: 20ext%20 ext{\%}
    • Alcohol risk thresholds discussed: men 60–80 g/day; women 40–60 g/day; sustained use increases risk of liver damage.
    • Acute liver failure criteria: INR > 1.51.5 and hepatic encephalopathy (neurologic dysfunction) with no prior history of liver disease; mortality is high without intervention.
    • Jaundice threshold: bilirubin level > 22 mg/dL is often cited as a sign of clinical jaundice, though symptoms vary.
    • Ascites fluids: up to 20 L or more of ascitic fluid can accumulate in the peritoneal cavity; paracentesis may remove 5–6 L at a time; albumin is typically infused to help maintain oncotic pressure.
    • Endoscopic surveillance for varices is recommended after a cirrhosis diagnosis; repeat intervals depend on variceal size (earlier and more frequent if present).
    • Typical dietary and nutrition targets: calories ~2500$-$3000 ext{ kcal/day}; protein 1.2 to 1.5 g/kg/day; sodium restriction around 500extmg/day500 ext{ mg/day} in ascites; vitamin supplementation (A, B1, B12, C, folic acid) and minerals (potassium) as part of a multivitamin.

Connections to broader concepts and real-world relevance

  • The liver’s central role in metabolism explains why liver disease has such widespread systemic effects, including coagulopathy (bleeding risk), immune dysregulation, nutritional deficiencies, altered mental status, and fluid balance abnormalities.
  • Vaccination, blood screening, and universal precautions have significantly reduced the incidence of hepatitis A and B since 1990, whereas hepatitis C has become more prominent due to IV drug use, though newer antiviral regimens have improved cure rates.
  • The management of cirrhosis and its complications (ascites, variceal bleeding, hepatic encephalopathy) requires integrated care: nutrition, pharmacologic therapy, procedures (paracentesis, endoscopy, shunts), and lifestyle changes (alcohol avoidance, weight management).
  • Ethical and practical implications include patient education on avoiding hepatotoxic substances, adherence to vaccination and preventive measures, and psychosocial support given the potential for progressive morbidity and impact on quality of life.

Quick reference glossary (from lecture content)

  • Asterixis: involuntary hand flapping, seen in hepatic encephalopathy.
  • Esophageal varices: dilated submucosal veins in the lower esophagus from portal hypertension; prone to life-threatening bleeding.
  • Paracentesis: procedure to remove ascitic fluid from the peritoneal cavity.
  • Lactulose (Seaculac): ammonia-lowering laxative used in hepatic encephalopathy.
  • MELD/Child-Pugh not explicitly discussed, but often used in cirrhosis management (noted as common clinical tools).

End of notes

If you want, I can convert these notes into a compact study sheet with sections you can memorize quickly, or expand any section with practice questions and quick-case scenarios.